Research Article

Non-Motor Fluctuations in Parkinson’s Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire

Galit Kleiner, MD1, Hubert H. Fernandez, MD2, Kelvin L. Chou MD3, Alfonso Fasano, MD PhD4,5, Kevin R. Duque MD6, Diana Hengartner MD2, Albie Law BA, CCRA1, Adam Margolius MD2, Yu-yan Poon RN4, Michel Sáenz Farret MD4, Philip Saleh MD MSc1, Joaquin A. Vizcarra MD6, Glenn T. Stebbins, PhD7, Alberto J. Espay, MD MSc6 on behalf of the PSG NoMoFA Study Group

1 Jeff and Diane Ross Movement Disorders Clinic/ATC, Baycrest Center for Geriatric Health, Toronto, Ontario, Canada. Division of Neurology, University of Toronto, Toronto, ON, Canada

2 Department of Neurology and Center for Neurological Restoration, Neurological Institute, Cleveland Clinic Lerner College of Medicine, Cleveland OH, USA

3 Departments of Neurology and Neurosurgery, University of Michigan Medical School, Ann Arbor MI, USA

4 Edmond J. Safra Program in Parkinson’s Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. Division of Neurology, University of Toronto, Toronto, ON, Canada

5Krembil Brain Institute, Toronto, ON, Canada

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/mds.28507

This article is protected by copyright. All rights reserved.
Corresponding author: Galit Kleiner MD, Jeff and Diane Ross Movement Disorders Clinic/ATC, Baycrest Center for Geriatric Health, 3560 Bathurst Street, Toronto, Ontario, Canada, M6A 2E1, email: Galit.Kleiner@assistivetechnologyclinic.ca, tel: 416-784-3600

Number of tables/figures: 4/0 (max 5)
Number of supplementary material: 2
Number of references: 39
Text word count: 3631 (max 3700)
Abstract word count: 240 (max 250)
Running title: Validation of nonmotor fluctuation questionnaire
Key-words: Non-motor fluctuations, non-motor symptoms, questionnaire, validation, Parkinson’s disease

Financial Disclosure/Conflict of Interest related to the manuscript:
The authors have no relevant disclosures relevant to this manuscript.

Funding source for the study: Sunovion Pharmaceuticals sponsorship through Parkinson Study Group
Abstract

Background: In patients with Parkinson’s disease (PD), sleep, mood, cognitive, autonomic and other non-motor symptoms may fluctuate in a manner similar to motor symptoms.

Objectives: To validate a final version of a patient-rated questionnaire that captures the presence and severity of non-motor fluctuations in levodopa-treated PD patients (NoMoFA).

Methods: We recruited PD subjects from 5 movement disorders centers across the US and Canada. We assessed the internal consistency, floor and ceiling effects, test-retest reliability and concurrent validity of NoMoFA. Classical test theory and item response theory methods informed item reduction and Delphi process yielded a final questionnaire.

Results: Two-hundred subjects and their care-partners participated in the study (age: 66.4 ± 9.6 years; disease duration: 9 ± 5.5 years; median Hoehn and Yahr [H&Y] OFF: 3 [range 1-5]; mean UPDRS III ON score: 27.4 ± 14.9). Acceptability of the scale was adequate. There were floor effects in 8/28 items. Cronbach’s alpha was 0.894. While eight items had “item-to-total” correlations below the cutoff of 0.4, removing these items did not improve Cronbach’s alpha. Test-retest reliability was acceptable (ICC = 0.73; 95th Confidence Interval, 0.64 - 0.80).

Concurrent validity was adequate with all Spearman’s rho values comparing NoMoFA score to other measures of parkinsonian severity showing significance and in the expected direction. A final Delphi panel eliminated one item to avoid redundancy.

Conclusions: The final 27-item self-administered NoMoFA is a valid and reliable questionnaire, capturing both static and fluctuating non-motor symptoms in PD.
INTRODUCTION

Non-motor fluctuations (NMF) are the dynamic subset of non-motor symptoms (NMS). NMF have increasingly been recognized as important and disabling symptoms of Parkinson’s disease (PD)\textsuperscript{1,2}. NMS may fluctuate in parallel with motor symptoms and in relationship to plasma dopamine concentration, although the exact mechanism of NMF remains speculative\textsuperscript{3,4}. It is important to differentiate static from fluctuating NMS as they may have different pathophysiology and response to treatment.

Recent recognition of the impact of NMS on quality of life has driven efforts to create valid, reliable questionnaires to capture and quantify NMS\textsuperscript{5,6,7}. Some of these questionnaires have included items probing selected non-motor OFF symptoms but none capture or quantify the entire spectrum of NMF in both the ON- and the OFF-medication conditions. We sought to create and validate a patient-rated questionnaire with the goal of reliably capturing and quantifying NMF to meet clinical and research needs.

METHODS

Initial scale development

An initial version of the Non-Motor Fluctuation Assessment (NoMoFA) questionnaire\textsuperscript{8} was created following the FDA guidance for development of patient-reported outcome (PRO) instruments\textsuperscript{9}. We used qualitative research methodology of patient-based nominal group technique and focus groups with framework analyses\textsuperscript{10} to identify NMS susceptible to fluctuations impacting the patient’s function. A Delphi panel\textsuperscript{11} composed of members from the Quality Standards Subcommittee on Non-Motor Symptoms in PD of the American Academy of...
Neurology\textsuperscript{12}, reviewed all available information (nominal group, focus group, literature review and professional experience), to develop an initial list of 28 items for the scale. The scoring of this initial scale identified a given NMS and asked if it was related to when levodopa was working (ON) or not (OFF), and rating the severity of the symptom (mild, moderate, severe) if ON or OFF.

\textit{Initial examination of clinimetric properties}

The clinimetric properties of this first version of NoMoFA were initially examined in a sample of 129 patients with PD, recruited from 3 specialized clinics, who completed the questionnaire on their own or with the assistance of a care-partner if needed. The study cohort’s mean age was 65.2 ± 10.1 years, had a disease duration of 6.3 ± 4.2 years, were 58\% men, and took 812.2 ± 418.9 mg levodopa-equivalent daily dose (LEDD)\textsuperscript{13}.

Basic clinimetric properties of this scale were examined including internal consistency (Cronbach’s alpha)\textsuperscript{14} and item-to-total correlation. The thresholds for acceptable alpha was ≥ 0.80\textsuperscript{15} and for acceptable item-to-total correlation ≥ 0.40\textsuperscript{16}. Multiple deficiencies in clinimetrics were noted, with ON items particularly poor for Cronbach’s alpha (0.733) and low item-to-total correlations (< 0.40).

It was determined that the item scaling and the scoring scheme for the scale were contributing to these poor clinimetric properties. The Delphi panel then modified the item scaling and the scoring scheme to first ask subjects if the behavior was present, then rated the severity of the behavior if present, and then indicated if the behavior was worse when ON, when OFF, or if there was no difference between ON and OFF. This modification was piloted in
a sample of 60 patients with the corresponding analysis demonstrating improved Cronbach’s alpha and item-to-total correlations.

The scale was then subjected to cognitive interviewing utilizing 6 new patient/care-partner dyads. During the cognitive interviews, participants were asked to review the questionnaire for item relevance, ease of understanding, and whether response choices were both exhaustive and mutually exclusive. Using the results of the cognitive interview, a penultimate questionnaire was finalized in preparation for further validation.

This penultimate NoMoFA was composed of 28 items: loss of train of thought, distraction, disorientation, difficulty planning, confusion, word-finding difficulty, excessive worry, fear, restlessness, hopelessness, loneliness/isolation, hallucinations, poor decision making, impulsivity, compulsiveness, poor short term memory, difficulty handling stressful situations, apathy, low energy/fatigue, excessive daytime sleepiness, pain, altered sensations (numbness, tingling), shortness of breath, changes in vision, excess sweating, palpitations, urinary symptoms, and constipation.

Sample size

Based on a sample size of 5 to 10 subjects for each scale item it was determined that a sample size of between 140 and 280 was necessary for examining the 28 items of the NoMoFA. Feasibility permitted target recruitment of 200, well above the suggested minimum subject-to-item ratio of 5.

Patients
English-speaking patients, with a diagnosis of idiopathic PD as per MDS clinical diagnostic criteria\textsuperscript{18}, and an available care-partner, were invited to participate from 5 Movement Disorders Centers across the US and Canada between September 2018 and September 2019. We sought patients with mild, moderate and advanced symptoms to include the entire spectrum of PD severity.

Exclusion criteria included atypical Parkinsonism and lack of English language fluency of either the patient or care-partner. While we did not impose a cognitive cut-off so as to not systematically exclude a significant portion of the population affected by NMF, we obtained cognitive scores using the Montreal Cognitive Assessment (MoCA)\textsuperscript{19} battery for reference. If a subject had cognitive impairment but a care-partner was able to assist in responding to the questionnaire, the combined response from the subject and care-partner dyad was included. If disagreement arose in those questionnaires with joint subject and care-partner responding, the subject’s answer was prioritized.

**Study Procedures**

The study was approved by the institutional review boards of each participating center and all participants signed informed consent. The consent process included obtaining consent from the caregiver and assent from the patient if they were deemed unable to provide consent due to cognitive impairment. Consecutive idiopathic PD patients presenting to each of the participating sites for their regular clinic appointments were screened for use of levodopa and fluctuating PD symptoms (both motor and non-motor) and invited to participate.
Subjects were recruited across the spectrum of disease severity (mild, Hoehn and Yahr (H&Y) stages 1-2; moderate, H&Y stage 3; severe, H&Y stages 4-5). Periodic review of enrolled study subjects facilitated the prioritization of under-represented severity categories.

Identified subjects were scheduled to return in their best “ON” state to optimally respond to questions (~1 hour after taking a dose of levodopa). Following provision of informed consent, the study team administered/collected the following data: the Movement Disorders Society-sponsored Unified Parkinson’s Disease Rating Scale (MDS-UPDRS part III)\textsuperscript{20} and the H&Y staging\textsuperscript{21}, baseline demographic information (age at diagnosis, gender), ON and OFF Schwab and England (S&E) activities of daily living scale, disease duration, medication dosage quantified as levodopa equivalent daily dose (LEDD)\textsuperscript{13}, and the Montreal Cognitive Assessment (MoCA)\textsuperscript{19} battery. The treating movement disorders physician was queried as to their impression regarding the presence and severity of the subject’s motor fluctuations (MF) and NMF (mild, moderate, severe).

The package of questionnaires included the NoMoFA questionnaire, MDS-UPDRS Part Ia Ib, II and IV, Scales for Outcomes in Parkinson’s Disease - Autonomic Dysfunction (SCOPA-AUT)\textsuperscript{22}, Parkinson’s Disease Questionnaire-8 (PDQ-8)\textsuperscript{23}, and Wearing-Off Questionnaire-9 (WOQ-9)\textsuperscript{24}. Questionnaires were packaged in random order that varied across administrations to nullify any potential order-effect. A sub-group of subjects were asked to complete the NoMoFA questionnaire a second time one week following the baseline visit and were provided with a self-addressed envelope to send to back to investigators. On this second NoMoFA
questionnaire, the subjects were asked to rate if they had experienced any change in their PD symptoms (motor and non-motor) and/or in their PD medications since the initial assessment 1 week earlier to ensure stability of symptoms and medications using the Clinical Global Impression Scale.

**Scoring of NoMoFA**

Endorsement of any item as present required scoring its severity as mild, moderate or severe (range 1-3). The total NoMoFA score was calculated as the sum of the severity scores for all items endorsed (total possible score: 28 items x 3 = 84). If the endorsed NMS item was worse in the ON or OFF state, that severity score was recorded in the “NMF ON” or “NMF OFF” column respectively. If the endorsed NMS item did not fluctuate, it was recorded in the “NMS no difference column.” The total NMF sub-score ON was the sum of all the “NMF ON” scores; the total NMF sub-score OFF the sum of all the “NMF OFF” scores. The “total NMF sub-score” was the sum of “NMF ON” and “NMF OFF” sub-scores. The total (static) NMS score was the sum of all “NMS no difference” scores. The total NoMoFA score was calculated using the following formula: Total NoMoFA = Total NMF (ON + OFF) + Total (static) NMS.

**Statistical Analysis**

Subject demographics and disease-related characteristics were examined using parametric and non-parametric analyses, as appropriate. Testing of clinimetric properties was conducted using both Classical Test Theory (CTT) and Item Response Theory (IRT). CTT analyses examined *Data Quality* for missing values and potential floor and ceiling effects.
defined as skewness outside of the range -2.00 to +2.00, Internal Consistency as determined by Cronbach’s alpha, with a minimum required alpha of 0.85, item-to-total correlation ≥ 0.40 as minimal acceptable correlation, and Construct Validity using exploratory factor analyses to determine the number and types of constructs with a minimum loading of 0.40 used as a criterion for factor relevance. Item redundancy was assessed by item loading on multiple factors. Dual loading criteria was set at 0.40. IRT analyses using maximum likelihood parameter estimation examined item discrimination (criterion of ≥ 1.00) and item threshold. Test-retest Reliability was assessed in a sample of 160 patients tested over a 1 week (±2.3 days) using intraclass correlation coefficients (ICC), with a criterion of ≥ 0.70 to indicate adequate stability. Concurrent Validity was assessed using Spearman’s rank-order correlation coefficient (rho) for assessing the relationship between the NoMoFA and MDS-UPDRS I, II, III, IV, WOQ-9, PDQ, MF score (as rated by physician), NMF score (also as rated by physician) SCOPA-AUT, S&E ON and OFF, and H&Y ON and OFF. We chose Spearman’s rank order correlations coefficient due to the underlying ordinal nature of the data. Frequency of endorsed NMS and NMF was calculated as the percent of total cases.

All statistical analyses were conducted using Mplus 8.2 (www.statmodel.com), R “mrit” package for the IRT analyses, and the rest of the analyses were conducted in SPSS Ver 24 (IBM).

RESULTS

Subjects

The packet of questionnaires was completed by 145 subjects without assistance, 35 subjects with assistance of their care-partner, and 2 care-partners without assistance from the
subject. Data on who was the respondent was missing from 18 questionnaires. On average it took ~ 10-20 minutes to complete the NoMoFA questionnaire. Study subject baseline information is included in Table 1.

The proportion of static and NMS and NMF are included in Table 2.

**Examination of clinimetric properties**

Data quality and acceptability characteristics indicated that the scale was well tolerated with 8 subjects missing one item and 5 subjects missing 2 items when answering the questionnaire. Eight items demonstrated potential floor effect as evidenced by skewness values >2.00. Examination of internal consistency indicated an acceptable level of reliability (Cronbach's alpha = 0.89) and 20 items had adequate item-to-total correlations (r ≥ 0.40) (Table 3). Eight items fell below this cut off, including Disorientation, Pain, Altered Sensations, Shortness of Breath, Changes in Vision, Excess Sweating, Urinary Symptoms and Constipation. Removing these items did not increase overall Cronbach's alpha.

**Construct validity** resulted in parsimonious 2-factor solution, with adequate sampling and sphericity (KMO adequacy = 0.856, Bartlett's test = X² = 1809.62, p < 0.0005), accounting for approximately 37 percent of the variance. There were no items with dual loadings > 0.40 and two items that that did not load on either factor (Altered Sensations and Excess Sweating).

**IRT discrimination** and thresholds values demonstrated adequate discrimination by most items. Five items fell below the criterion of ≤ 1.00 (Disorientation, Hallucinations, Pain, Altered Sensations and Shortness of Breath), although none of these fell below a discrimination value of 0.50.
Test-retest reliability for the total NoMoFA score was adequate (ICC= 0.73 [95% CI 0.64-0.79]). Temporal stability for the individual items as assessed using a weighted Kappa coefficient with linear weighting demonstrated stability with values > 0.3 for all measures except 3 (Fear/Feeling Scared K = 0.294; Impulsiveness K = 0.297; Apathy/Loss of Interest K=0.298).

Concurrent validity. Spearman’s rho correlation coefficient compared the NoMoFA score to other measures of Parkinsonian severity (Table 4). Correlation values were all in expected direction (negative for S&E, positive for all others) with higher correlation with other NMS surveys and measures of quality of life.

Final Questionnaire Designation

Following data analysis, investigators reconvened the Delphi panel to review results and discuss possible item reduction. Further analysis of 4 items that performed sub-optimally demonstrated that the Spearman’s correlation between the “Disorientation” item and “Confusion” items was 0.294 and the correlation between “Poor Decision Making” and “Impulsiveness” was 0.481. The relatively low correlation between “Disorientation” and “Confusion” was hypothesized to be due to the low frequency of endorsement of “Disorientation” as an item. The panel decided that “Disorientation” would be removed from the final questionnaire as the item related to “Confusion” sufficiently overlapped and would capture this construct. The Panel also decided to retain both “Poor Decision Making” and “Impulsiveness” in the final questionnaire despite clinimetric testing inconsistencies, as these were clinically important and distinct constructs. The Panel agreed that all other items were
clinically relevant and that while some may have shown floor effects, this could have been due to the fact that the sample was not completely represented by those of greater disease severity.

The final validated NoMoFA questionnaire is provided in Supplementary Material 1. The final scoring table is provided in Supplementary Material 2. Based on removal of one item from NoMoFA there were a total of 27 items in the final questionnaire with a total maximum possible score for the NoMoFA of 81 (27x3).

DISCUSSION

The NoMoFA, developed as a patient-derived and self-administered questionnaire using qualitative research methods that impart substantial face and construct validity, was found to be valid and reliable in capturing both static and fluctuating non-motor symptoms in PD. In creating the NoMOFA questionnaire, there was deliberate intention to integrate patient input in the development of the scale from its inception, to include only items relevant to patients' own functional abilities and not easily rated by outside observers. The self-rated framework was aimed at reducing the burden of administration as well to provide a questionnaire that could be accessed remotely in an era where both clinical care and research are increasingly shifting to remote applications with the assistance of technology.

An additional priority when conceptualizing the NoMoFA, was to be able to identify the proportion of NMS that fluctuate (‘true’ NMF) as well as the proportion of those that do not (‘static’ NMS). By providing a comprehensive survey of an individual’s complete experience
with NMS both static and in the ON and OFF states, NoMoFA has relevant application for measuring the effect of therapeutic interventions designed to reduce both NMS and NMF.

Other NMS instruments have been developed that include a subset of NMFs as part of the overall score. The recently validated Movement Disorder Society Non-Motor Rating Scale (MDS-NMS)\(^3\) is a 52-item rater-administered survey of NMS with an 8 item NMF subscale. The items are not differentiated into their ON versus OFF presence, reflecting only the time spent in the OFF state. Item selection for the MDS-NMS was based on the non-motor symptoms scale (NMSS)\(^3\), expert opinion, literature review, and included patient input through cognitive pretesting and administration of the preliminary version of the MDS-NMS. The NMSS\(^3\) developed in 2007 and subsequently modified by Storch and colleagues\(^3\), indirectly captures NMF. The NMF score is derived as the difference between NMSS scores in the ON versus the OFF state. While this instrument likely identifies NMFs, the need to apply the 30-item clinician-administered scale in both the ON state and the OFF state is labor-intensive and may not lend itself readily to research and clinical practice. The self-administered Wearing-Off Questionnaire (WOQ)\(^2\) has gone through several iterations initially starting as 33 items, then reduced to 19 items, and finally a 9-item questionnaire (WOQ-9), which was found to be as valid and reliable as the longer versions. The WOQ-9 combines 5 motor and 4 non-motor items limited to items in the OFF state and was developed based on expert opinion with no patient input.

Two commonly used scales that include ratings of NMS do not include NMF. The validated non-motor experiences of daily living sub-scale of the Unified Parkinson Disease Rating Scale (MDS-UPDRS Ia and Ib)\(^2\) includes items on cognitive, mood and behavioral
symptoms, autonomic symptoms, sleep dysfunction, and sensory symptoms, but it does not address fluctuations in these symptoms. The Scales for Outcomes in Parkinson Disease - autonomic dysfunction (SCOPA-AUT)\textsuperscript{22} is a reliable and valid measure of autonomic NMS in PD, but it too does not address fluctuations in symptoms.

We intended to recruit a representative sample to maximize generalizability of the application of NoMoFA in diverse patient populations. We elected not to exclude those with moderate or severe cognitive impairment from the sample (MoCA score was not exclusionary), despite the concern that reduced cognition would jeopardize the quality of the data by not providing reliable responses. We intentionally included these subjects in recognition that those with more advanced illness were also more likely to experience greater fluctuations in their symptoms\textsuperscript{36}. We accommodated this limitation by including patient/care-partner dyads where the care-partner was able to reliably report the symptoms as a surrogate if the patient was struggling to answer independently. We did not examine differences in clinimetric properties between scales completed by patients alone versus scales completed by patients and their care-partner due to the limited sample size of the latter group and the potential for truncated variance. This examination would be interesting to conduct in a planned analysis in future studies.

Our examination of the clinimetric properties of the NoMoFA demonstrated adequate results. Most items met our criteria for acceptance. Those few that did not were either removed from the scale or were determined by the Delphi panel to be of sufficient clinical
importance to be included even with sub-optimal clinimetric properties. This is an important consideration in developing clinical rating scales; the inclusion of items should not be driven solely by consideration of the statistics\textsuperscript{37}. In addition, all items demonstrated adequate test-retest stability, an important marker of reliability. This is significant in that reliability is the rate-limiting factor in a scale’s validity\textsuperscript{38}.

In assessing concurrent validity, we sought to include as many questionnaires as possible to reflect the wide spectrum of non-motor symptoms while balancing this with the concern for respondent fatigue. As such, we limited the number of questionnaires at the expense of potentially excluding relevant additional questionnaires addressing constructs such as pain or fatigue. Nonetheless, the direction of all correlations with respect to the questionnaires we included was appropriate, with strongest correlations between MDS-UPDRS I (non-motor symptoms), PDQ-8, MDS-UPDRS II, NMF-severity (Physician-rated), as well as negative correlations with the ON and OFF S&E, as predicted. The correlation between the NoMoFA and the PDQ-8 suggests that greater NMF burden correlates with worse quality of life. The concurrent validity results suggest that the NoMoFA correlates to the largest extent with other questionnaires capturing NMS more than with those measuring motor symptoms, and with those questionnaires that capture fluctuating symptoms more than static symptoms.

Interestingly, while MF-severity (Physician-rated), WOQ-9, and UPDRS IV were positively correlated with NMF, the strength of correlation was less robust, further suggesting that MF and NMF may not be of equal magnitude and may have a different impact in an individual, with some studies suggesting NMF driving a greater reduction in quality of life than MF\textsuperscript{1}. 
The NoMoFA uniquely captured static and fluctuating symptoms within individuals. Interestingly, fatigue was endorsed as both the most frequent overall NMS in a vast majority of subjects, and the NMS that most frequently fluctuates among all subjects. Likewise, word-finding difficulty, loss of train of thought, excessive daytime sleepiness, pain and restlessness, frequently fluctuated. This has direct treatment implications for people with PD, as these NMS are often managed as non-dopamine-sensitive symptoms, with significant treatment failures and negative impact on quality of life. The recognition within an individual patient of which symptom is static and which fluctuates would allow a more precise and likely effective approach to symptom management. Indeed, cognitive symptoms like word-finding difficulties and loss of train of thought frequently herald a diagnosis of dementia with limited treatment options; recognition that these symptoms could be improved with modification of dopamine-mediated strategies has significant implications on function and independence.

Our study has several limitations. Interim review of enrollment approximately halfway into the study revealed that a disproportionate number of subjects were either mild or moderate in disease severity. As such, efforts increased to preferentially enroll subjects classified as severe, however, despite this, only 21% of the subjects enrolled were ultimately classified as severe. Our challenge with recruiting advanced patients was similar to other studies, notably the recent MDS-NMS validation study that also had a predominant mild-moderate cohort. This is not surprising given the increased challenge of more severely affected people with PD to attend outpatient subspecialty clinics. Patients in later stage of illness may be placed in long-term care given their high care-needs and therefore excluded from the pool of willing and capable participants involved in research.
Conclusion

The NoMoFA is the first valid and reliable comprehensive patient-derived and patient-administered questionnaire that captures and quantifies NMF. It has been created through a methodologically rigorous process with focus group and cognitive interviewing input, Delphi panel deliberations, and two large scale validations, to produce a final survey of static and fluctuating NMS. Integration of NoMoFA into clinical practice and research protocols will be expected to facilitate efficient and effective customization of treatment strategies and augment the value of future research endeavors particularly for therapies that may improve NMS/NMF. Future work will include determination of the minimal clinically important difference in NoMoFA scores and its sensitivity to change (responsivity) with interventions. This will inform our understanding of the natural history of NMF, its relationship to other symptoms, and its impact on quality of life.

Authors Roles:

1) Research project: A. Conception, B. Organization, C. Execution
3) Manuscript: A. Writing of the first draft, B. Review and Critique

GK: 1A, 1B, 2C,3A,
HHF: 1A, 1B, 2C, 3B
KLC: 1A, 2C, 3B
AF: 1A, 2C, 3B
KRD: 1C, 3B
DH: 1C, 3B
AL:1B, 1C, 3B
AM: 1C, 3B
YYP: 1C, 3B  
MSF: 1C, 3B  
PS: 1C, 3B  
JAV: 1C, 3B  
GTS: 1A, 2A, 2B, 3A  
AJE: 1A, 1B, 2C, 3B

Financial Disclosures of all authors (for the preceding 12 months)

<table>
<thead>
<tr>
<th>GK</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stock Ownership in medically-related fields</strong></td>
</tr>
<tr>
<td><strong>Intellectual Property Rights</strong></td>
</tr>
<tr>
<td><strong>Consultancies</strong></td>
</tr>
<tr>
<td><strong>Expert Testimony</strong></td>
</tr>
<tr>
<td><strong>Advisory Boards</strong></td>
</tr>
<tr>
<td><strong>Employment</strong></td>
</tr>
<tr>
<td><strong>Partnerships</strong></td>
</tr>
<tr>
<td><strong>Contracts</strong></td>
</tr>
<tr>
<td><strong>Honoraria</strong></td>
</tr>
<tr>
<td><strong>Royalties</strong></td>
</tr>
<tr>
<td><strong>Grants</strong></td>
</tr>
<tr>
<td><strong>Other</strong></td>
</tr>
</tbody>
</table>

HHF
<table>
<thead>
<tr>
<th>Stock Ownership in medically-related fields</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intellectual Property Rights</td>
<td>None</td>
</tr>
<tr>
<td>Consultancies</td>
<td>Sunovion Research and Development Trust</td>
</tr>
<tr>
<td>Expert Testimony</td>
<td>None</td>
</tr>
<tr>
<td>Advisory Boards</td>
<td>None</td>
</tr>
<tr>
<td>Employment</td>
<td>None</td>
</tr>
<tr>
<td>Partnerships</td>
<td>None</td>
</tr>
<tr>
<td>Contracts</td>
<td>The Cleveland Clinic has a contract with Teva for Dr. Fernandez’ role as a Co-Principal Investigator in Deutetrabenazine for Tardive Dyskinesia global studies.</td>
</tr>
<tr>
<td>Honoraria</td>
<td>Cleveland Clinic (2K), Boston University, New York University (.75) as a speaker in CME events. Dr. Fernandez has received honoraria from Bial Neurology(4K), Biopas (1.3), Cerevel, CNS Ratings (22), Covance (1), Kyowa Hakko Kirin (3.2), Partners Healthcare System (20), Parkinson Study Group (11.5), Revance (1.8), Sun Pharmaceutical Industries (5), Elsevier as the Editor-In-Chief of <em>Parkinsonism and Related Disorders</em> Journal</td>
</tr>
<tr>
<td>Royalties</td>
<td>Demos Publishing, Springer</td>
</tr>
<tr>
<td>Grants</td>
<td>Acorda Therapeutics, Alkahest, Amneal, Biogen, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Sunovion</td>
</tr>
<tr>
<td>Other</td>
<td>None</td>
</tr>
<tr>
<td>Stock Ownership in medically-related fields</td>
<td>None</td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Intellectual Property Rights</td>
<td>None</td>
</tr>
<tr>
<td>Consultancies</td>
<td>Accordant CNS Ratings</td>
</tr>
<tr>
<td>Expert Testimony</td>
<td>None</td>
</tr>
<tr>
<td>Advisory Boards</td>
<td>None</td>
</tr>
<tr>
<td>Employment</td>
<td>None</td>
</tr>
<tr>
<td>Partnerships</td>
<td>None</td>
</tr>
<tr>
<td>Contracts</td>
<td>None</td>
</tr>
<tr>
<td>Honoraria</td>
<td>None</td>
</tr>
<tr>
<td>Royalties</td>
<td>UpToDate Springer Publishing</td>
</tr>
<tr>
<td>Grants</td>
<td>NIH (NS091856-01, NS10061102, NS107158) Parkinson Study Group (STEADY-PD III, SURE-PD3, NILO-PD, NoMoFA, RAD-PD) Eli Lilly, Voyager Therapeutics</td>
</tr>
<tr>
<td>Other</td>
<td>None</td>
</tr>
</tbody>
</table>

AF

<table>
<thead>
<tr>
<th>Stock Ownership in medically-related fields</th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intellectual Property Rights</td>
<td>None</td>
</tr>
<tr>
<td>Consultancies</td>
<td>Abbvie, Abbott, Medtronic, Boston Scientific, Ceregate. Ipsen</td>
</tr>
<tr>
<td>Expert Testimony</td>
<td>None</td>
</tr>
<tr>
<td>Advisory Boards</td>
<td>Abbvie, Abbott, Boston Scientific, Ipsen</td>
</tr>
<tr>
<td>Employment</td>
<td>None</td>
</tr>
<tr>
<td>Partnerships</td>
<td>None</td>
</tr>
<tr>
<td>Contracts</td>
<td>None</td>
</tr>
<tr>
<td>Honoraria</td>
<td>Abbvie, Abbott, Medtronic, Boston Scientific, UCB, Ipsen</td>
</tr>
<tr>
<td>Royalties</td>
<td>None</td>
</tr>
<tr>
<td>Grants</td>
<td>Abbvie, Medtronic, Boston Scientific</td>
</tr>
<tr>
<td>Other</td>
<td>None</td>
</tr>
</tbody>
</table>

AM: Served on Advisory Board September 2019 for Acadia Pharmaceuticals
KRD, DH, AL, AM, YYP, MSF, PS, JAV- none

GTS

<table>
<thead>
<tr>
<th></th>
<th>None</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Stock Ownership in medically-related fields</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Intellectual Property Rights</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Expert Testimony</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Employment</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Partnerships</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Contracts</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Honoraria</strong></td>
<td>International Parkinson and Movement Disorder Society, American Academy of Neurology, Michael J. Fox Foundation for Parkinson’s Research, Food and Drug Administration, National Institutes of Health, Alzheimer’s Association</td>
</tr>
<tr>
<td><strong>Royalties</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Grants</strong></td>
<td>National Institutes of Health, Department of Defense, Michael J. Fox Foundation for Parkinson’s Research, Dystonia Coalition, CHDI, Cleveland Clinic Foundation, International Parkinson and Movement Disorder Society, CBD Solutions.</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>None</td>
</tr>
<tr>
<td>Stock Ownership in medically-related fields</td>
<td>None</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Intellectual Property Rights</td>
<td>None</td>
</tr>
<tr>
<td>Consultancies</td>
<td>Abbvie, Neuroderm, Neurocrine, Amneal, Acadia, Acorda, InTrance, Sunovion, Lundbeck, and USWorldMeds</td>
</tr>
<tr>
<td>Expert Testimony</td>
<td>None</td>
</tr>
<tr>
<td>Advisory Boards</td>
<td>Abbvie, Neuroderm, Neurocrine, Amneal, Acadia, Acorda, InTrance, Sunovion, Lundbeck, and USWorldMeds</td>
</tr>
<tr>
<td>Employment</td>
<td>None</td>
</tr>
<tr>
<td>Partnerships</td>
<td>None</td>
</tr>
<tr>
<td>Contracts</td>
<td>None</td>
</tr>
<tr>
<td>Honoraria</td>
<td>USWorldMeds, Acadia, Sunovion</td>
</tr>
<tr>
<td>Royalties</td>
<td>None</td>
</tr>
<tr>
<td>Grants</td>
<td>NIH and Michael J Fox Foundation</td>
</tr>
<tr>
<td>Other</td>
<td>None</td>
</tr>
</tbody>
</table>

References


14. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;


24. Stacy MA, Murphy JM, Greeley DR, Stewart RM, Murck H, Meng X. The sensitivity and specificity of the 9-item Wearing-off Questionnaire. Park Relat Disord. 2008;


COPYRIGHT TRANSFER AGREEMENT

Date: 26 Dec 2020

Contributor name: Albie Law

Contributor address: 39 Windyton Ave., Markham, ON L6B 0X6

Manuscript number: MDS-20-1258. R2

Re: Manuscript entitled: Non-Motor Fluctuations in PD:
Validation of the Non-Motor Fluctuation Assessment Questionnaire

for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

---

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSped@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgment since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgment section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[✓] Contributor-owned work

Contributor’s signature

Date

Type or print name and title

Co-Contributor’s signature

Date

Type or print name and title
[_____] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire) Date

Authorized signature of Employer Date

Contributor’s signature Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[_____] U.S. Government work
Note to U.S. Government Employees
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[_____] U.K. Government work (Crown Copyright)
Note to U.K. Government Employees
The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[_____] Other
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees
If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A
Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: N/A
Address: 
Type of support: 

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: N/A
Address: 
Type of support: 

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY
COPYRIGHT TRANSFER AGREEMENT

Date: 12/26/2020
Contributor name: Adam Margolius
Contributor address: 9500 Euclid Ave / S2, Cleveland OH 44195
Manuscript number: MDS-20-1258-R2
Re: Manuscript entitled: Non-Motor Fluctuations in PD: Validation of the Non-Motor Fluctuation Assessment Questionnaire
for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or

b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, PDF/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ ] Contributor-owned work

Contributor’s signature

[ ] NIH grantee

Date

Type or print name and title

Co-Contributor’s signature

Type or print name and title

Adam Maigolins MD

12/26/20
[_____] Company/Institution-owned Work (made-for-hire in the Course of employment)

Company or Institution (Employer-for-Hire)  Date

Authorized signature of Employer  Date

Contributor’s signature  Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[_____] U.S. Government work
Note to U.S. Government Employees
A contribution prepared by a U.S. federal government employee as part of the employee’s official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor’s signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[_____] U.K. Government work (Crown Copyright)
Note to U.K. Government Employees
The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[_____] Other
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees
If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _______________________
Address: ______________________
Type of support: ______________________

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _______________________
Address: ______________________
Type of support: ______________________

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY
COPYRIGHT TRANSFER AGREEMENT

Date: Nov 13, 2020

Contributor name: Galit Kleiner

Contributor address: University of Toronto

Manuscript number: MDS-20-1258

Re: Manuscript entitled: "Non-motor fluctuations in PD: Validation..." (the “Contribution”) for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: [Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[X] Contributor-owned work

Galit Kleiner

October 19 2020

Contributor’s signature

Date

Galit Kleiner

Type or print name and title

Co-Contributor’s signature

Date

Type or print name and title
<table>
<thead>
<tr>
<th>Company/Institution-owned Work (made-for-hire in the Course of employment)</th>
<th>Company or Institution (Employer-for-Hire)</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authorized signature of Employer</td>
<td>Date</td>
<td></td>
</tr>
<tr>
<td>Contributor's signature</td>
<td>Date</td>
<td></td>
</tr>
<tr>
<td>Type or print name and title</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY**

<table>
<thead>
<tr>
<th>[_____] U.S. Government work</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Note to U.S. Government Employees</strong></td>
</tr>
<tr>
<td>A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a &quot;U.S. Government work&quot;, and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>[_____] U.K. Government work (Crown Copyright)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Note to U.K. Government Employees</strong></td>
</tr>
<tr>
<td>The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>[_____] Other</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Including Other Government work or Non-Governmental Organisation work</strong></td>
</tr>
<tr>
<td><strong>Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees</strong></td>
</tr>
</tbody>
</table>
| If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: Galit Kleiner
Address: University of Toronto
Type of support: Investigator initiated trial- Sunovion (PSG)

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: 
Address: 
Type of support: 

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

Stock Ownership in medically-related fields Stock held in Eli Lilly and Co and Merck and Co
Intellectual Property Rights Owner of US patent No. 10,098,932 Botulinum toxin for use in the treatment of paratonia
Consultancies None
Expert Testimony None
Advisory Boards Sunovion Pharmaceuticals, Allergan, Abbvie, Ipsen
Employment None
Partnerships None
Contracts None
Honoraria Ipsen, Abbvie
Royalties None
Grants PSG-NoMOFA
Other None
COPYRIGHT TRANSFER AGREEMENT

Date: 10/21/20

Contributor name: Kelvin L. Chou, MD

Contributor address: 2301 Commonwealth Blvd. Ann Arbor, MI 48105

Manuscript number: MDS-20-1258

Re: Manuscript entitled: Non-Motor Fluctuations in PD: Validation of the Non-Motor Fluctuation Assessment Questionnaire (the "Contribution") for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: [Title of Article, Contributor, Journal Title and Volume/Issue, Copyright © [year] The International Parkinson and Movement Disorder Society]. An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or receives funding from these agencies. The details of those arrangements, and other arrangements allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or

b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[X] Contributor-owned work

[Signature]

Contributor’s signature

[Date]

Date

Kelvin L. Chou, MD

Type or print name and title

[Signature]

Co-Contributor’s signature

[Date]

Type or print name and title
[ ] Company/Institution-owned Work (made-for-hire in the Course of employment)

Company or Institution (Employer-for-Hire)  Date

Authorized signature of Employer  Date

Contributor's signature  Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[ ] U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[ ] U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[ ] Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.


Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Investigator initiated grant support: Sunovion Pharmaceuticals

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Grants:
NIH (NS107158)
Parkinson Study Group (STEADY-PD III, SURE-PD3, NILO-PD, RAD-PD)
Eli Lilly
Voyager Therapeutics
Neuraly

Consulting:
Accordant
CNS Ratings
Watermark Research Partners, Inc.

Royalties:
UpToDate
Springer Publishing
COPYRIGHT TRANSFER AGREEMENT

Date: __________________________

Contributor name: Alberto J. Espay

Contributor address: University of Cincinnati

Manuscript number: # MDS-20-1258

Re: Manuscript entitled: "Non-Motor Fluctuations in PD: Validation..." (the “Contribution”) for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal Title]: (Title of Article, Contributor, Journal Title and Volume/Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or

b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ ] Contributor-owned work

Alberto Espay
Contributor’s signature
Date

Type or print name and title

Co-Contributor’s signature
Date

Type or print name and title
[_____] Company/Institution-owned Work (made-for-hire in the Course of employment)  

Company or Institution (Employer-for-Hire)  

Date  

Authorized signature of Employer  

Date  

Contributor’s signature  

Date  

Type or print name and title  

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY  

[_____] U.S. Government work  
Note to U.S. Government Employees  
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.  

[_____] U.K. Government work (Crown Copyright)  
Note to U.K. Government Employees  
The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.  

[_____] Other  
Including Other Government work or Non-Governmental Organisation work  
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees  
If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: Sunovion
Address: __________________________
Type of support: Investigator-initiated study grant support

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Alberto J. Espay
Address: University of Cincinnati
Type of support: See below

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

Dr. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Abbvie, Neuroderm, Neurocrine, Amneal, Adamas, Acadia, Acorda, InTrance, Sunovion, Lundbeck, and USWorldMeds; publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer; and honoraria from USWorldMeds, Acadia, and Sunovion.
COPYRIGHT TRANSFER AGREEMENT

Date: Oct 21 2020  
Contributor name: Alfonso Fasano  
Contributor address: Movement Disorders Centre, Toronto Western Hospital  
Manuscript number: MDS-20-1258  
Re: Manuscript entitled: Non-Motor Fluctuations in Parkinson’s Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire  
for publication in: Movement Disorders (the “Journal”)  
Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)  

Dear Contributor(s):  

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT  
The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS  
Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR  

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. **Required Citation.** Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal Title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.Wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. **Accepted Version.** Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. **Additional Terms for Certain Funders.** Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or

b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. **Additional Terms for Certain Institutions.** Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ ] Contributor-owned work

Alfonso Fasano

Contributor’s signature

Alfonso Fasano

Type or print name and title

Oct 21 2020

Date

Co-Contributor’s signature

Date

Type or print name and title
<table>
<thead>
<tr>
<th>Company/Institution-owned Work (made-for-hire in the Course of employment)</th>
<th>Company or Institution (Employer-for-Hire)</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Authorized signature of Employer</td>
<td></td>
<td>Date</td>
</tr>
<tr>
<td>Contributor's signature</td>
<td></td>
<td>Date</td>
</tr>
<tr>
<td></td>
<td>Type or print name and title</td>
<td></td>
</tr>
</tbody>
</table>

**ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY**

<table>
<thead>
<tr>
<th>[ ] U.S. Government work</th>
</tr>
</thead>
</table>

**Note to U.S. Government Employees**

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

<table>
<thead>
<tr>
<th>[ ] U.K. Government work (Crown Copyright)</th>
</tr>
</thead>
</table>

**Note to U.K. Government Employees**

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

<table>
<thead>
<tr>
<th>[ ] Other</th>
</tr>
</thead>
</table>

**Including Other Government work or Non-Governmental Organisation work**

**Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees**

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
**Exhibit A**

**Financial Disclosure**

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: **None** Sunovion

Address: 

Type of support: **investigator-initiated study grant support**

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: **see below**

Address: 

Type of support: 

This material will be posted on the journal website and may be printed at the Editors’ discretion.

**ATTACH ADDITIONAL INFORMATION AS NECESSARY**

- Stock Ownership in medically-related fields: **None**
- Intellectual Property Rights: **None**
- Consultancies: Abbvie, Abbott, Medtronic, Boston Scientific, Ceregate, Ipsen
- Expert Testimony: **None**
- Advisory Boards: Abbvie, Abbott, Boston Scientific, Ipsen
- Employment: **None**
- Partnerships: **None**
- Contracts: **None**
- Honoraria: Abbvie, Abbott, Medtronic, Boston Scientific, UCB, Ipsen
- Royalties: **None**
- Grants: Abbvie, Medtronic, Boston Scientific
- Other: **None**
COPYRIGHT TRANSFER AGREEMENT

Date: 12/28/2020

Contributor name: Diana C. Hengartner MD

Contributor address: 25 N Winfield Rd Ste 432, Winfield, IL 60190 Northwestern Medicine Movement Disorders

Manuscript number: MDS-20-1258

Re: Manuscript entitled: "Non-motor fluctuations in PD: Validation..." (the “Contribution”) for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or

b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ X] Contributor-owned work

Contributor’s signature ❌

12/28/2020

Date

Diana C. Hengartner MD

Type or print name and title

Co-Contributor’s signature ❌

Date

Type or print name and title
[_____] Company/Institution-owned Work (made-for-hire in the Course of employment)

Company or Institution (Employer-for-Hire) Date

Authorized signature of Employer Date

Contributor’s signature Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[_____] U.S. Government work

Note to U.S. Government Employees
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[_____] U.K. Government work (Crown Copyright)

Note to U.K. Government Employees
The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[_____] Other
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees
If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.

__________________________________________

__________________________________________
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: n/a
Address: 
Type of support: 

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: n/a
Address: 
Type of support: 

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY
COPYRIGHT TRANSFER AGREEMENT

Date: 10/28/20

Contributor name: HUBERT H. FERNANDEZ

Contributor address: 9500 EUCLID AVE, CLEVELAND CLINIC, OH

Manuscript number: MOS 20 - 1258

Re: Manuscript entitled: NON MOTION FLUCTUATIONS IN PARKINSON DISEASE: VALIDATION OF

for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any...
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or

b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[X] Contributor-owned work

[ ] NIH grantee

Contributor’s signature

Date

HUBERT H. FERNANDEZ

Type or print name and title

Co-Contributor’s signature

Date

Type or print name and title
[Company/Institution-owned Work (made-for-hire in the Course of employment)]

Company or Institution (Employer-for-Hire) ________________________________ Date

Authorized signature of Employer ________________________________ Date

Contributor’s signature ________________________________ Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[ ] U.S. Government work
Note to U.S. Government Employees
A contribution prepared by a U.S. federal government employee as part of the employee’s official duties, or which is an official U.S. Government publication, is called a “U.S. Government work”, and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor’s signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee’s duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[ ] U.K. Government work (Crown Copyright)
Note to U.K. Government Employees
The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[ ] Other
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees
If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: ____________NONE__________
Address: __________________________
Type of support: __________________________

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: ____________HUBERT A. FERNANDEZ__________
Address: ____________see attached__________
Type of support: __________________________

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

See attached
Disclosure Statement of Hubert H. Fernandez, MD over the past 12 months:

*Grants/Research Support:* Dr. Fernandez has received research support from Acorda Therapeutics, Alkahest, Amneal, Biogen, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Sunovion, but has no owner interest in any pharmaceutical company.

*Honoraria:* Dr. Fernandez has received honoraria from, Cleveland Clinic (2K), Boston University, New York University (.75) as a speaker in CME events. Dr. Fernandez has received honoraria from Bial Neurology(4K), Biopas (1.3), Cerevel, CNS Ratings (22), Covance (1), Kyowa Hakko Kirin (3.2), Partners Healthcare System (20), Parkinson Study Group (11.5), Revance (1.8), Sun Pharmaceutical Industries (5), Sunovion Research and Development Trust as a consultant. Elsevier as the Editor-In-Chief of *Parkinsonism and Related Disorders* Journal

*Royalty:* Dr. Fernandez has received royalty payments from Demos Publishing and Springer for serving as a book author/editor.

*Contractual Services:* The Cleveland Clinic has a contract with Teva for Dr. Fernandez' role as a Co-Principal Investigator in Deutetrabenazine for Tardive Dyskinesia global studies.
COPYRIGHT TRANSFER AGREEMENT

Date: 12/26/2020

Contributor name: Kevin R. Duque

Contributor address: University of Cincinnati, 260 Stetson St., Cincinnati, Ohio, 45267, USA

Manuscript number: MDS-20-1258

Re: Manuscript entitled: Non-Motor Fluctuations in PD: Validation of the Non-Motor Fluctuation Assessment Questionnaire (the “Contribution”) for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systemic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable. If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ ] Contributor-owned work

Kevin R. Duque

[ ] NIH grantee

Kevin R. Duque, M.D.

Type or print name and title

Co-Contributor’s signature

Type or print name and title

Digitally signed by Kevin Duque

12/26/2020

Date
[_____] Company/Institution-owned Work (made-for-hire in the Course of employment)  

Company or Institution (Employer-for-Hire)  

Date

Authorized signature of Employer  

Date

Contributor’s signature  

Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[_____] U.S. Government work  

Note to U.S. Government Employees  

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[_____] U.K. Government work (Crown Copyright)  

Note to U.K. Government Employees  

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[_____] Other  

Including Other Government work or Non-Governmental Organisation work  

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees  

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: N/A
Address: N/A
Type of support: N/A

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: N/A
Address: N/A
Type of support: N/A

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY
COPYRIGHT TRANSFER AGREEMENT

Date: 26/Dec/2020

Contributor name: Michel Sáenz-Farret

Contributor address: 399 Bathurst St, Toronto, ON M5T 2S8, Canada

Manuscript number: MDS-20-1258.R2

Non-Motor Fluctuations in PD: Validation of the Non-Motor Fluctuation Assessment Questionnaire

Re: Manuscript entitled: Non-Motor Fluctuations in PD: Validation of the Non-Motor Fluctuation Assessment Questionnaire (the “Contribution”) for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ X ] Contributor-owned work

Contributor’s signature    Date

Michel Sáenz-Farret, MD

Type or print name and title

Co-Contributor’s signature    Date

Type or print name and title
[________] Company/Institution-owned Work (made-for-hire in the Course of employment)

Company or Institution (Employer-for-Hire) Date

__________________________
Authorized signature of Employer Date

__________________________
Contributor’s signature Date

__________________________
Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[________] U.S. Government work

Note to U.S. Government Employees
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[________] U.K. Government work (Crown Copyright)

Note to U.K. Government Employees
The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[________] Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees
If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: _________________________
Address: _______________________
Type of support: ___________________

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: _________________________
Address: _______________________
Type of support: ___________________

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY
COPYRIGHT TRANSFER AGREEMENT

Date: 12/27/2020

Contributor name: Joaquín Vizcarra

Contributor address: 12 Executive Park Dr NE Atlanta, GA 30329

Manuscript number: ________________

Re: Manuscript entitled: NoMoFa (the “Contribution”) for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any
systematic external distribution (e.g., posting on a listserv, public website, database connected to a public
access server, or automated delivery system). The license grant in this Section does not apply to for-profit
corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing
by the Owner. The rights granted to Contributor under this Section C do not include reproduction,
distribution or any other use of rating scales, videos or other audiovisual materials associated with the
Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement
of the Journal in all preprints in the following format: This is a preprint of an article accepted for
publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder
Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the
following format: This is a preprint of an article that was published in [Journal title]: (Title of Article,
Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and
Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at
http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the
published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version
of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate
arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms
apply if the Contributor receives or received funding from these agencies. The details of those relationships,
and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/
funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research
Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository
after an embargo period. Details of funding arrangements are set out at the following website:
http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the
production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option,
the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository
after the following applicable embargo period has expired, subject to further conditions imposed by the
RCUK:

   a. 12 months from first publication online of the final published version of the Contribution for
       research funded by members of the Research Councils UK (RCUK) other than The
       Economic and Social Research Council (ESRC) and the Arts and Humanities Research
       Council (AHRC); or
   b. 24 months from first publication online of the final published version of the Contribution for
       research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational
institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo
period. Details of such arrangements are set out at the following website:
http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s
OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in
the educational institution’s repository after the following applicable embargo period has expired. See the
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ ] Contributor-owned work

<table>
<thead>
<tr>
<th>Contributor’s signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Type or print name and title

Joaquin Vizcarra

<table>
<thead>
<tr>
<th>Co-Contributor’s signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12/27/2020</td>
</tr>
</tbody>
</table>

Joaquin A. Vizcarra, M.D.

Type or print name and title
<table>
<thead>
<tr>
<th>Company/Institution-owned Work (made-for-hire in the Course of employment)</th>
<th>Company or Institution (Employer-for-Hire)</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Authorized signature of Employer</td>
<td>Date</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributor’s signature</td>
<td>Date</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Type or print name and title</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[_____] **U.S. Government work**

*Note to U.S. Government Employees*

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[_____] **U.K. Government work (Crown Copyright)**

*Note to U.K. Government Employees*

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[_____] **Other**

Including Other Government work or Non-Governmental Organisation work

*Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees*

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: ________________________
Address: ______________________
Type of support: ______________________
This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: ________________________
Address: ______________________
Type of support: ______________________
This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY
COPYRIGHT TRANSFER AGREEMENT

Date: 10/21/20
Contributor name: Glenn T. Stebbins
Contributor address: Rush University Medical Center
Manuscript number: MDS-20-1258
Re: Manuscript entitled: Non-Motor Fluctuations in Parkinson's Disease...
for publication in: Movement Disorders (the "Journal")

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the "Owner")

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or
b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s’) physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ X ] Contributor-owned work

[Contributor’s signature] 10/21/20

Glenn T. Stebbins, PhD

Type or print name and title

[Co-Contributor’s signature] Date

[Type or print name and title]
Company/Institution-owned Work (made-for-hire in the Course of employment)

Authorized signature of Employer

Contributor's signature

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[_____] U.S. Government work
Note to U.S. Government Employees
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[_____] U.K. Government work (Crown Copyright)
Note to U.K. Government Employees
The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[_____] Other
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees
If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: Glenn T. Stebbins
Address: 
Type of support: none

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: Glenn T. Stebbins
Address: 
Type of support: see below

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY

Grants and Research: National Institutes of Health, Department of Defense, Michael J. Fox Foundation for Parkinson’s Research, Dystonia Coalition, CHDI, Cleveland Clinic Foundation, International Parkinson and Movement Disorder Society, CBD Solutions.
Honoraria: International Parkinson and Movement Disorder Society, American Academy of Neurology, Michael J. Fox Foundation for Parkinson’s Research, Food and Drug Administration, National Institutes of Health, Alzheimer’s Association.
Intellectual Property Rights: none
Ownership interests: none
Royalties: none
COPYRIGHT TRANSFER AGREEMENT

Date: Nov. 16, 2020

Contributor name: Philip Saleh

Contributor address: 3560 Bathurst Street, Toronto, ON, M6A 2E1

Manuscript number: MDS-20-1258

Re: Manuscript entitled: Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire

for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. **Publication cannot proceed without a signed copy of this Agreement.**

**A. COPYRIGHT**

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

**B. RETAINED RIGHTS**

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

**C. PERMITTED USES BY CONTRIBUTOR**

1. **License.** The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserv, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

   a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or

   b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://olabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://olabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ X ] Contributor-owned work

Contributor’s signature ___________________________ Date 11/16/2020

Dr. Philip Saleh

Type or print name and title

Co-Contributor’s signature ___________________________ Date

Type or print name and title
[ ] Company/Institution-owned Work (made-for-hire in the Course of employment)  
Company or Institution (Employer-for-Hire)  Date

Authorized signature of Employer  Date

Contributor's signature  Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[ ] U.S. Government work
Note to U.S. Government Employees
A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[ ] U.K. Government work (Crown Copyright)
Note to U.K. Government Employees
The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[ ] Other
Including Other Government work or Non-Governmental Organisation work
Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees
If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: Philip Saleh
Address: 3560 Bathurst Street, Toronto, ON, M6A 2E1
Type of support: Fellowship salary support

This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: ______________________
Address: ______________________
Type of support: ______________________

This material will be posted on the journal website and may be printed at the Editors’ discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY
Table 1. Baseline study subject characteristics

<table>
<thead>
<tr>
<th></th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects (N)</td>
<td>200</td>
</tr>
<tr>
<td>Age (Mean (years), SD)</td>
<td>66.4 ± 9.6</td>
</tr>
<tr>
<td>Gender</td>
<td>54% men 46% women</td>
</tr>
<tr>
<td>Disease Duration (Mean (years), SD)</td>
<td>9 ± 5.5</td>
</tr>
<tr>
<td>LEDD (Mean, SD)</td>
<td>1102.18 mg ±650.16 mg</td>
</tr>
<tr>
<td>MOCA score (Mean, SD)</td>
<td>25 ± 4</td>
</tr>
<tr>
<td>H&amp;Y ON</td>
<td></td>
</tr>
<tr>
<td>Mild (H+Y 0-2)</td>
<td>58.3%</td>
</tr>
<tr>
<td>Moderate (H+Y 2.5, 3)</td>
<td>30.1%</td>
</tr>
<tr>
<td>Severe (H+Y 4, 5)</td>
<td>11.6%</td>
</tr>
<tr>
<td>H&amp;Y OFF</td>
<td></td>
</tr>
<tr>
<td>Mild</td>
<td>43.4%</td>
</tr>
<tr>
<td>Moderate</td>
<td>35.7%</td>
</tr>
<tr>
<td>Severe</td>
<td>21%</td>
</tr>
<tr>
<td>S+E ON (Median, Range)</td>
<td>90%, 20-100</td>
</tr>
<tr>
<td>S+E OFF (Median, Range)</td>
<td>80% 10-100</td>
</tr>
<tr>
<td>MDS-UPDRS 1 (Mean, SD)</td>
<td>14.62 ± 7.18</td>
</tr>
<tr>
<td>MDS-UPDRS 2 (Mean, SD)</td>
<td>14.93 ± 8.20</td>
</tr>
<tr>
<td>MDS-UPDRS 3 (ON) (Mean, SD)</td>
<td>27.39 ± 14.85</td>
</tr>
<tr>
<td>MDS-UPDRS 4 (Mean, SD)</td>
<td>7.2 ± 3.45</td>
</tr>
<tr>
<td>NoMoFA Total (Mean, SD)</td>
<td>19.57 ± 11.97</td>
</tr>
</tbody>
</table>

Table 2: Frequency of non-motor symptoms (NMS) with proportion of static and fluctuating NMS (NMF)

<table>
<thead>
<tr>
<th>NMS</th>
<th>Frequency of NMS (%)</th>
<th>Static NMS (%)</th>
<th>Fluctuating NMS (NMF) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low energy/fatigue</td>
<td>86.4</td>
<td>50.5</td>
<td>49.5</td>
</tr>
<tr>
<td>Word finding difficulty</td>
<td>76.0</td>
<td>64.8</td>
<td>35.2</td>
</tr>
<tr>
<td>Loss of train of thought</td>
<td>73.0</td>
<td>62.5</td>
<td>37.5</td>
</tr>
<tr>
<td>Pain</td>
<td>69.7</td>
<td>64.3</td>
<td>35.7</td>
</tr>
<tr>
<td>Restlessness</td>
<td>66.0</td>
<td>61.5</td>
<td>38.5</td>
</tr>
<tr>
<td>Word finding difficulty</td>
<td>76.0</td>
<td>64.8</td>
<td>35.2</td>
</tr>
<tr>
<td>Urinary symptoms</td>
<td>62.8</td>
<td>84.8</td>
<td>15.2</td>
</tr>
<tr>
<td>Distraction (difficulty completing task)</td>
<td>60.5</td>
<td>71.0</td>
<td>29.0</td>
</tr>
<tr>
<td>Excessive daytime sleepiness</td>
<td>59.6</td>
<td>65.3</td>
<td>34.7</td>
</tr>
<tr>
<td>Constipation</td>
<td>54.0</td>
<td>87.4</td>
<td>12.6</td>
</tr>
<tr>
<td>Difficulty handling stressful situations</td>
<td>51.8</td>
<td>77.0</td>
<td>23.0</td>
</tr>
<tr>
<td>Altered sensations</td>
<td>47.7</td>
<td>77.4</td>
<td>22.6</td>
</tr>
<tr>
<td>Changes in vision</td>
<td>46.7</td>
<td>85.5</td>
<td>14.5</td>
</tr>
<tr>
<td>Difficulty planning an activity</td>
<td>44.5</td>
<td>73.5</td>
<td>26.5</td>
</tr>
<tr>
<td>Excessive worry</td>
<td>41.5</td>
<td>82.9</td>
<td>17.1</td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>38.5</td>
<td>87.0</td>
<td>13.0</td>
</tr>
<tr>
<td>Loneliness/isolation</td>
<td>34.5</td>
<td>86.4</td>
<td>13.6</td>
</tr>
<tr>
<td>Sadness/helplessness</td>
<td>31.2</td>
<td>84.9</td>
<td>15.1</td>
</tr>
<tr>
<td>Apathy/loss of interest</td>
<td>30.2</td>
<td>86.8</td>
<td>13.2</td>
</tr>
<tr>
<td>Excess sweating</td>
<td>29.0</td>
<td>88.0</td>
<td>12.0</td>
</tr>
<tr>
<td>Poor decision making</td>
<td>24.1</td>
<td>92.5</td>
<td>7.5</td>
</tr>
<tr>
<td>Palpitations</td>
<td>22.5</td>
<td>90.0</td>
<td>10.0</td>
</tr>
<tr>
<td>Impulsiveness</td>
<td>22.1</td>
<td>92.0</td>
<td>8.0</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>21.0</td>
<td>88.0</td>
<td>12.0</td>
</tr>
<tr>
<td>Fear/feeling scared</td>
<td>19.5</td>
<td>88.5</td>
<td>11.5</td>
</tr>
<tr>
<td>Confusion</td>
<td>19.0</td>
<td>87.5</td>
<td>12.5</td>
</tr>
<tr>
<td>Compulsions/uncontrollable urges</td>
<td>18.5</td>
<td>94.5</td>
<td>5.5</td>
</tr>
<tr>
<td>Disorientation</td>
<td>17.5</td>
<td>88.5</td>
<td>11.5</td>
</tr>
</tbody>
</table>
Table 3. Clinimetric properties of NoMoFA items

<table>
<thead>
<tr>
<th>Item</th>
<th>Missing</th>
<th>Skewness</th>
<th>80th %tile</th>
<th>Corrected Item-Total Correlation</th>
<th>Cronbach's Alpha if Item Deleted</th>
<th>Factor 1 Loading</th>
<th>Factor 2 Loading</th>
<th>IRT Discrimination</th>
<th>Test-Retest Weighted Kappa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loss of train of thought</td>
<td>0</td>
<td>0.266</td>
<td>2</td>
<td>0.418</td>
<td>0.893</td>
<td>0.685</td>
<td>1.094</td>
<td>0.488</td>
<td></td>
</tr>
<tr>
<td>Distraction (difficulty completing task)</td>
<td>0</td>
<td>0.651</td>
<td>2</td>
<td>0.539</td>
<td>0.891</td>
<td>0.639</td>
<td>1.063</td>
<td>0.446</td>
<td></td>
</tr>
<tr>
<td>Difficulty planning an activity</td>
<td>0</td>
<td>1.054</td>
<td>2</td>
<td>0.510</td>
<td>0.892</td>
<td>0.422</td>
<td>1.443</td>
<td>0.393</td>
<td></td>
</tr>
<tr>
<td>Disorientation</td>
<td>1</td>
<td>2.649</td>
<td>1</td>
<td>0.362</td>
<td>0.895</td>
<td>0.433</td>
<td>0.720</td>
<td>0.370</td>
<td></td>
</tr>
<tr>
<td>Confusion</td>
<td>0</td>
<td>2.399</td>
<td>1</td>
<td>0.495</td>
<td>0.892</td>
<td>0.387</td>
<td>1.508</td>
<td>0.415</td>
<td></td>
</tr>
<tr>
<td>Word finding difficulty</td>
<td>0</td>
<td>0.200</td>
<td>2</td>
<td>0.520</td>
<td>0.892</td>
<td>0.655</td>
<td>1.049</td>
<td>0.464</td>
<td></td>
</tr>
<tr>
<td>Excessive worry</td>
<td>0</td>
<td>0.927</td>
<td>2</td>
<td>0.670</td>
<td>0.888</td>
<td>0.637</td>
<td>2.314</td>
<td>0.559</td>
<td></td>
</tr>
<tr>
<td>Fear (feeling scared)</td>
<td>0</td>
<td>2.236</td>
<td>1</td>
<td>0.527</td>
<td>0.892</td>
<td>0.590</td>
<td>2.216</td>
<td>0.294</td>
<td></td>
</tr>
<tr>
<td>Restlessness</td>
<td>0</td>
<td>0.468</td>
<td>2</td>
<td>0.574</td>
<td>0.890</td>
<td>0.517</td>
<td>1.401</td>
<td>0.461</td>
<td></td>
</tr>
<tr>
<td>Sadness/hopelessness</td>
<td>1</td>
<td>1.474</td>
<td>2</td>
<td>0.574</td>
<td>0.890</td>
<td>0.732</td>
<td>2.738</td>
<td>0.395</td>
<td></td>
</tr>
<tr>
<td>Loneliness/isolation</td>
<td>0</td>
<td>1.459</td>
<td>1</td>
<td>0.586</td>
<td>0.890</td>
<td>0.691</td>
<td>2.592</td>
<td>0.439</td>
<td></td>
</tr>
<tr>
<td>Hallucinations</td>
<td>0</td>
<td>2.269</td>
<td>1</td>
<td>0.431</td>
<td>0.893</td>
<td>0.497</td>
<td>0.755</td>
<td>0.673</td>
<td></td>
</tr>
<tr>
<td>Poor decision making</td>
<td>1</td>
<td>2.274</td>
<td>1</td>
<td>0.504</td>
<td>0.892</td>
<td>0.430</td>
<td>2.234</td>
<td>0.440</td>
<td></td>
</tr>
<tr>
<td>Impulsiveness</td>
<td>1</td>
<td>2.268</td>
<td>1</td>
<td>0.411</td>
<td>0.894</td>
<td>0.375</td>
<td>1.342</td>
<td>0.297</td>
<td></td>
</tr>
<tr>
<td>Compulsions/uncontrollable urges</td>
<td>0</td>
<td>2.427</td>
<td>1</td>
<td>0.434</td>
<td>0.893</td>
<td>0.398</td>
<td>1.325</td>
<td>0.455</td>
<td></td>
</tr>
<tr>
<td>Poor short-term memory</td>
<td>0</td>
<td>0.345</td>
<td>2</td>
<td>0.496</td>
<td>0.892</td>
<td>0.644</td>
<td>1.072</td>
<td>0.532</td>
<td></td>
</tr>
<tr>
<td>Difficulty handling</td>
<td>2</td>
<td>0.670</td>
<td>2</td>
<td>0.633</td>
<td>0.889</td>
<td>0.543</td>
<td>1.567</td>
<td>0.454</td>
<td></td>
</tr>
<tr>
<td>stressful situations</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apathy/loss of interest</td>
<td>2</td>
<td>1.605</td>
<td>2</td>
<td>0.535</td>
<td>0.891</td>
<td>0.582</td>
<td>1.915</td>
<td>0.298</td>
<td></td>
</tr>
<tr>
<td>Low energy/fatigue</td>
<td>1</td>
<td>-0.128</td>
<td>3</td>
<td>0.513</td>
<td>0.891</td>
<td>0.468</td>
<td>1.499</td>
<td>0.413</td>
<td></td>
</tr>
<tr>
<td>Excessive daytime sleepiness</td>
<td>2</td>
<td>0.549</td>
<td>2</td>
<td>0.453</td>
<td>0.893</td>
<td>0.362</td>
<td>1.112</td>
<td>0.480</td>
<td></td>
</tr>
<tr>
<td>Pain</td>
<td>2</td>
<td>0.212</td>
<td>3</td>
<td>0.334</td>
<td>0.896</td>
<td>0.362</td>
<td>0.528</td>
<td>0.431</td>
<td></td>
</tr>
<tr>
<td>Altered sensations</td>
<td>1</td>
<td>0.811</td>
<td>2</td>
<td>0.286</td>
<td>0.896</td>
<td></td>
<td>0.648</td>
<td>0.370</td>
<td></td>
</tr>
<tr>
<td>Shortness of breath</td>
<td>0</td>
<td>1.319</td>
<td>2</td>
<td>0.383</td>
<td>0.894</td>
<td>0.440</td>
<td>0.924</td>
<td>0.621</td>
<td></td>
</tr>
<tr>
<td>Changes in vision</td>
<td>1</td>
<td>0.710</td>
<td>2</td>
<td>0.364</td>
<td>0.895</td>
<td></td>
<td>0.314</td>
<td>1.917</td>
<td>0.524</td>
</tr>
<tr>
<td>Excess sweating</td>
<td>0</td>
<td>1.757</td>
<td>1</td>
<td>0.303</td>
<td>0.896</td>
<td></td>
<td>1.260</td>
<td>0.546</td>
<td></td>
</tr>
<tr>
<td>Palpitations</td>
<td>0</td>
<td>2.304</td>
<td>1</td>
<td>0.411</td>
<td>0.894</td>
<td>0.485</td>
<td>1.493</td>
<td>0.401</td>
<td></td>
</tr>
<tr>
<td>Urinary symptoms</td>
<td>1</td>
<td>0.331</td>
<td>2</td>
<td>0.356</td>
<td>0.895</td>
<td></td>
<td>0.315</td>
<td>1.447</td>
<td>0.545</td>
</tr>
<tr>
<td>Constipation</td>
<td>2</td>
<td>0.538</td>
<td>2</td>
<td>0.327</td>
<td>0.896</td>
<td>0.310</td>
<td>2.012</td>
<td>0.576</td>
<td></td>
</tr>
</tbody>
</table>
Table 4. Concurrent validity: Correlations with other instruments

<table>
<thead>
<tr>
<th>instrument</th>
<th>Correlation Coefficient rho</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDS-UPDRS Part 1 Non-Motor Experiences of Daily Living</td>
<td>0.753</td>
</tr>
<tr>
<td>PDQ-8</td>
<td>0.686</td>
</tr>
<tr>
<td>MDS-UPDRS Part 2 Motor Experiences of Daily Living</td>
<td>0.568</td>
</tr>
<tr>
<td>NMF severity (Physician Rating)</td>
<td>0.458</td>
</tr>
<tr>
<td>S+E OFF</td>
<td>-0.442</td>
</tr>
<tr>
<td>MF Severity (Physician rating)</td>
<td>0.399</td>
</tr>
<tr>
<td>H+Y OFF</td>
<td>0.376</td>
</tr>
<tr>
<td>MDS-UPDRS Part 4 Complications of Therapy</td>
<td>0.359</td>
</tr>
<tr>
<td>S+E ON</td>
<td>-0.326</td>
</tr>
<tr>
<td>H+Y ON</td>
<td>0.302</td>
</tr>
<tr>
<td>WOQ-9</td>
<td>0.295</td>
</tr>
<tr>
<td>MDS-UPDRS Part 3 Motor Examination</td>
<td>0.277</td>
</tr>
</tbody>
</table>

COPYRIGHT TRANSFER AGREEMENT

Date: Dec 28, 2020

Contributor name: [Redacted]

Contributor address: 299 Bathurst St, Toronto, ON, Canada

Manuscript number: MDS 20-1258

Re: Manuscript entitled: Non-Motor Fluctuations PD (the “Contribution”)

for publication in: Movement Disorders (the “Journal”)

Published by Wiley on behalf of The International Parkinson and Movement Disorder Society (the “Owner”)

Dear Contributor(s):

Thank you for submitting your Contribution for publication. In order to expedite the editing and publishing process and enable the Owner to disseminate your Contribution to the fullest extent, we need to have this Copyright Transfer Agreement executed. If the Contribution is not accepted for publication, or if the Contribution is subsequently rejected, this Agreement shall be null and void. Publication cannot proceed without a signed copy of this Agreement.

A. COPYRIGHT

The Contributor assigns to the Owner, during the full term of copyright and any extensions or renewals, all copyright in and to the Contribution, and all rights therein, including but not limited to the right to reproduce, publish, republish, transmit, sell, transfer, distribute, and otherwise use the Contribution in whole or in part in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so.

B. RETAINED RIGHTS

Notwithstanding the above, the Contributor or, if applicable, the Contributor’s employer, retains all proprietary rights other than copyright, such as patent rights, in any process, procedure or article of manufacture described in the Contribution. This reservation of rights does not affect or limit the rights assigned to Owner in Section A.

C. PERMITTED USES BY CONTRIBUTOR

1. License. The Owner grants to Contributor a non-exclusive, non-transferable and limited license to reproduce and distribute copies of the print or electronic “preprints” of the unpublished Contribution, in the original form submitted to the Journal prior to the peer review process, solely to colleagues within the Contributor’s nonprofit organization or educational institution. The Contributor shall make no more than 100 printed copies of the preprints in any calendar year. Such preprints may be posted as electronic files on the Contributor’s own personal website, on the Contributor’s internal intranet at Contributor’s nonprofit organization or educational institution, or on a secure external website at the Contributor’s nonprofit organization or educational institution, provided that access is limited to employees and/or students at Contributor’s non-profit organization or educational institution. Contributor shall not charge a fee for any
preprints, and Contributor’s use under this Section C shall not be for any commercial purpose, or for any systematic external distribution (e.g., posting on a listserve, public website, database connected to a public access server, or automated delivery system). The license grant in this Section does not apply to for-profit corporations, and any proposed use outside of the scope of this Section C must be pre-approved in writing by the Owner. The rights granted to Contributor under this Section C do not include reproduction, distribution or any other use of rating scales, videos or other audiovisual materials associated with the Contribution.

2. Required Citation. Prior to publication, the Contributor must provide full credit and acknowledgement of the Journal in all preprints in the following format: This is a preprint of an article accepted for publication in [Journal Title], Copyright © [year] The International Parkinson and Movement Disorder Society. After publication, the Contributor must provide a citation to the Journal in all preprints in the following format: This is a preprint of an article that was published in [Journal title]: (Title of Article, Contributor, Journal Title and Volume/ Issue, Copyright © [year] The International Parkinson and Movement Disorder Society). An electronic link must be provided to the Journal’s website, located at http://www.interscience.wiley.com. The Contributor agrees not to update the preprint or replace it with the published version of the Contribution.

3. Accepted Version. Re-use of the accepted and peer-reviewed (but not the final typeset published) version of the Contribution (the “Accepted Version”) is not permitted under this Agreement. There are separate arrangements with certain funding agencies governing reuse of the Accepted Version. Additional terms apply if the Contributor receives or received funding from these agencies. The details of those relationships, and other offerings allowing open web use, are set forth at the following website: http://www.wiley.com/go/funderstatement.

4. Additional Terms for Certain Funders. Certain funders, including the NIH, members of the Research Councils UK (RCUK) and Wellcome Trust require deposit of the Accepted Version in a public repository after an embargo period. Details of funding arrangements are set out at the following website: http://www.wiley.com/go/funderstatement. Additional terms may be applicable. Please contact the production editor for the journal at MDSprod@wiley.com if you have additional funding requirements.

If any Contributor receiving funds from applicable sources does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in a public repository after the following applicable embargo period has expired, subject to further conditions imposed by the RCUK:

a. 12 months from first publication online of the final published version of the Contribution for research funded by members of the Research Councils UK (RCUK) other than The Economic and Social Research Council (ESRC) and the Arts and Humanities Research Council (AHRC); or

b. 24 months from first publication online of the final published version of the Contribution for research funded by ESRC or AHRC.

5. Additional Terms for Certain Institutions. Wiley has arrangements with certain educational institutions to permit the deposit of the Accepted Version in the institutional repository after an embargo period. Details of such arrangements are set out at the following website: http://onabout.wiley.com/WileyCDA/Section/id-406074.html. Additional terms may be applicable.

If any Contributor affiliated with these applicable educational institutions does not choose the Owner’s OnlineOpen option, the Contributor will be allowed to self-archive by depositing the Accepted Version in the educational institution’s repository after the following applicable embargo period has expired. See the following website for details: http://onabout.wiley.com/WileyCDA/Section/id-817011.html.
D. CONTRIBUTIONS OWNED BY EMPLOYER

If the Contribution was written by the Contributor in the course of the Contributor’s employment (as a “work-made-for-hire” in the course of employment), the Contribution is owned by the company/institution which must execute this Agreement (in addition to the Contributor’s signature). In such case, the company/institution hereby assigns to the Owner, during the full term of copyright, all copyright in and to the Contribution for the full term of copyright throughout the world as specified in Section A above.

E. GOVERNMENT CONTRACTS

In the case of a Contribution prepared under U.S. Government contract or grant, the U.S. Government may reproduce, without charge, all or portions of the Contribution and may authorize others to do so, for official U.S. Government purposes only, if the U.S. Government contract or grant so requires. (U.S. Government, U.K. Government, and other government employees: see notes at end.)

F. CONTRIBUTOR’S REPRESENTATIONS

The Contributor represents that the Contribution is the Contributor’s original work, all individuals identified as Contributors actually contributed to the Contribution, and all individuals who contributed are included. The Contribution is submitted only to this Journal and has not been published before. (If excerpts from copyrighted works owned by third parties are included, the Contributor will obtain written permission from the copyright owners for all uses as set forth in the Journal’s Instructions for Contributors, and show credit to the sources in the Contribution.) The Contributor also warrants that the Contribution contains no libelous or unlawful statements, does not infringe upon the rights (including without limitation the copyright, patent or trademark rights) or the privacy of others, or contain material or instructions that might cause harm or injury. Upon request, Contributor will provide the data or will cooperating fully in obtaining and providing the data on which the Contribution is based for examination by the editors or their assignees.

G. FINANCIAL DISCLOSURES

The Contributor certifies that his/her financial and material support for this research and work, regardless of date, is clearly identified on Exhibit A to this Agreement. The Contributor has also identified on Exhibit A, all other support unrelated to this research, covering the past year from the date of submission (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields).

H. VIDEO AND PHOTOGRAPHY CONSENT

In the event that the Contribution includes, discloses or incorporates any content (including, without limitation, any video clip or photograph) which identifies any individual patient(s) (“patient identifiable content”), the Contributor obtained from such patient(s) written consent to such inclusion, disclosure or incorporation and that this consent fully complies with all legal requirements, including without limitation, all of the requirements of the laws of the jurisdiction(s) to which the patient(s) and the patient(s)’ physician are subject, including the United States Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) if applicable. The Contributor hereby certifies that, if the patient consent form is in a language other than English, such consent form meets all of the requirements set forth in the Instructions to Authors. In addition, the Contributor hereby confirms that he/she obtained from patient(s) written consent to use the patient identifiable content in both print and online (i.e., internet/web-based) publication formats. The Contributor further certifies that the person executing any such patient consent form, to the best of his/her knowledge, had legal capacity under applicable law to execute the form on behalf of the patient.
I. ACKNOWLEDGEMENTS

The Contributor should obtain written permission from all individuals named in the acknowledgement since readers may infer their endorsement of data and conclusions. The Contributor certifies that all individuals named in the acknowledgement section have provided written permission to be named.

J. MISCELLANEOUS

This Agreement may be amended or modified only in a writing executed by both parties. The waiver or failure of any party to exercise any rights under this Agreement shall not be deemed a waiver or other limitation of any other right or any future right. This Agreement shall inure to the benefit of, and shall be binding upon, the parties, their respective successors and permitted assigns. This Agreement may be executed in two (2) or more counterparts, each of which shall be an original and all of which taken together shall constitute one and the same agreement. Executed copies of this Agreement may be delivered by facsimile transmission, pdf/email or other comparable electronic means. If for any reason any provision of this Agreement shall be deemed by a court of competent jurisdiction to be legally invalid or unenforceable, the validity, legality and enforceability of the remainder of this Agreement shall not be affected and such provision shall be deemed modified to the minimum extent necessary to make such provision consistent with applicable law and, in its modified form, such provision shall then be enforceable and enforced. The parties agree to do such further acts and to execute and deliver such additional agreements and instruments from time to time as either may at any time reasonably request in order to assure and confirm unto such requesting party the rights, powers and remedies conferred in the Agreement. This Agreement, including any exhibits attached hereto, contains the entire agreement and understanding of the parties with respect to the subject matter hereof, and supersedes all prior agreements, negotiations, representations and proposals, written and oral, relating thereto.

All Contributors must sign below. Contributors must check one box except that NIH grantees should check both Contributor-owned work and the NIH grantee box. If your Contribution was written during the course of employment, your employer must also sign where indicated.

Please send your original completed and signed forms by fax or email a scanned copy to the Journal production editor. For production editor contact details please visit the Journal’s online author guidelines. Do not send in hard copies of these forms.

[ ] Contributor-owned work

<table>
<thead>
<tr>
<th>Contributor’s signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Type or print name and title

[ ] Co-Contributor’s signature

<table>
<thead>
<tr>
<th>Co-Contributor’s signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dec 28, 2020</td>
</tr>
</tbody>
</table>

Type or print name and title
[ ] Company/Institution-owned
Work (made-for-hire in the
Course of employment)

Company or Institution (Employer-for-Hire)  

[ ] Date

Authorized signature of Employer

[ ] Date

Contributor's signature

[ ] Date

Type or print name and title

ATTACH ADDITIONAL SIGNATURE PAGES AS NECESSARY

[ ] U.S. Government work

Note to U.S. Government Employees

A contribution prepared by a U.S. federal government employee as part of the employee's official duties, or which is an official U.S. Government publication, is called a "U.S. Government work", and is in the public domain in the United States. In such case, Paragraph A.1 will not apply but the Contributor must type his/her name (in the Contributor's signature line) above. Contributor acknowledges that the Contribution will be published in the United States and other countries. If the Contribution was not prepared as part of the employee's duties or is not an official U.S. Government publication, it is not a U.S. Government work.

[ ] U.K. Government work (Crown Copyright)

Note to U.K. Government Employees

The rights in a contribution prepared by an employee of a UK government department, agency or other Crown body as part of his/her official duties, or which is an official government publication, belong to the Crown. Contributors must ensure they comply with departmental regulations and submit the appropriate authorisation to publish. If your status as a government employee legally prevents you from signing this Agreement, please contact the Journal production editor.

[ ] Other

Including Other Government work or Non-Governmental Organisation work

Note to Non-U.S., Non-U.K. Government Employees or Non-Governmental Organisation Employees

If your status as a government or non-governmental organisation employee legally prevents you from signing this Agreement, please contact the Journal production editor.
Exhibit A

Financial Disclosure

The Contributor has received financial and material support for this research and work regardless of date from the following sources:

Name: ____________________
Address: ____________________
Type of support: ____________________
This material will be printed with the published article.

In the past year from the date of submission, the Contributor has also received the following support unrelated to this research (e.g., grants, advisory boards, employment, consultancies, contracts, honoraria, royalties, expert testimony, partnerships, or stock ownership in medically-related fields):

Name: ____________________
Address: ____________________
Type of support: ____________________
This material will be posted on the journal website and may be printed at the Editors' discretion.

ATTACH ADDITIONAL INFORMATION AS NECESSARY